- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
BLRX Market Currents
more »
-
March 5 BioLineRx (BLRX) +7.2% premarket after saying it received approval to start a Phase II trial of its BL-7040 oral treatment for inflammatory bowel disease. A successful clinical trial could herald a breakthrough in the treatment of IBD, as many current treatments cause severe side effects and are ineffective in up to 40% of patients.
Comment![Healthcare, On the Move]
BLRX in Focus
more »
BLRX Related Articles
more »
BLRX News
more »
Currently, there are no news on BLRX.
BLRX Press Releases and Filings
more »
Currently, there are no press releases or filings on BLRX.
BLRX Latest Transcript
more »
Currently, there are no transcripts for BLRX.
BLRX Cramer
more »
Currently, there are no Cramer articles on BLRX.
BLRX Instablog posts
more »
Currently, there are no Instablog posts on BLRX.
BLRX vs. ETF Alternatives
Company Description
BioLineRx, Ltd. operates as a clinical-stage biopharmaceutical development company worldwide. Its clinical therapeutic candidates under development include BL-1020, a Phase IIb completed product for the treatment of schizophrenia; BL-1040, a Phase I/II clinical trial completed medical device... More
